الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 169 |  |  |
| | | from | 169 | | |
Abstract
Hepatitis C is an infectious disease affecting the liver, caused by HCV. The infection is often asymptomatic, but once established, chronic infection can progress to scarring of the liver (fibrosis), and advanced scarring (cirrhosis) which is generally apparent after many years. In some cases, those with cirrhosis will go on to develop liver failure or other complications of cirrhosis, including liver cancer.
The aim of this work was to determine serum levels of IP10 in patients with liver cirrhosis treated with sofosbuvir, ribavirin and IFN with or without previous treatment. We determined the concentrations of serum IP-10 and its correlation to the HCV activity and the degree of liver fibrosis.
This study was carried out on 27 CHC patients, 13 males and 14 females, admitted to Shebin El-Kome Fever Hospital. CBC, liver and kidney function tests, PCR and serum IP-10 levels were measured. The degree of liver fibrosis was assessed by fibroscan. 27 patients were submitted for IP-10 serum level evaluation after one week and after 3 months treatment with sofosbuvir , ribavirin and PEG-INF.
The study results revealed that:
1- chronic hepatitis C patients have significant elevation in serum levels of IP-10.
2- Serum IP-10 concentration was significantly reduced following a successful course of antiviral treatment.
3- The levels of serum IP-10 were correlated positively with the viral load of HCV.
4- The levels of serum IP-10 were correlated positively with the concentrations of ALT and AST in CHC patients.
5- Serum levels of IP-10 showed a significant association with Child-Pugh and MELD scores.
6- Serum IP-10 levels differed significantly among patients with different stages of fibrosis with higher levels in the advanced fibrosis stages.